1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with propofol in 1 studies
| Studies (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Trials (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Recent Studies (post-2010) (1-hexadecyl-2-acetyl-glycero-3-phosphocholine) | Studies (propofol) | Trials (propofol) | Recent Studies (post-2010) (propofol) |
|---|---|---|---|---|---|
| 9,156 | 187 | 552 | 16,827 | 5,188 | 6,805 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chap, H; Fourcade, O; Litt, L; Samii, K; Simon, MF | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and propofol
| Article | Year |
|---|---|
Propofol inhibits human platelet aggregation induced by proinflammatory lipid mediators.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Anesthetics, Intravenous; Blood Platelets; Calcium; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Inflammation Mediators; Lysophospholipids; Platelet Activating Factor; Platelet Aggregation; Propofol; Receptors, Cell Surface; Thromboxane A2 | 2004 |